



NANOFILM TECHNOLOGIES INTERNATIONAL LIMITED
 (Company Registration Number 199902564C)
 (Incorporated in Singapore on 13 May 1999)

GRANT OF SHARE OPTIONS PURSUANT TO THE NANOFILM EMPLOYEE SHARE OPTION SCHEME

The Board of Directors of Nanofilm Technologies International Limited (the “**Company**”) refers to the section entitled “*Appendix F – Rules of the Nanofilm Employee Share Option Scheme*” of the Company’s prospectus dated 23 October 2020 (the “**Prospectus**”), which sets out the details of the rules and administration of the Company’s Employee Share Option Scheme (“**ESOS**”)

Pursuant to Rule 704(29) of the Listing Manual of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”), the Directors wish to announce that the Company has on 6 April 2021 granted a total of 1,020,000 share options (the “**Options**”) to certain eligible participants and the independent directors of the Company (the “**Grantees**”) under the ESOS. Subject to the acceptance of the Grantees, the Options will entitle the Grantees to subscribe for a total of 1,020,000 new shares in the capital of the Company (each, a “**Share**”, and collectively, the “**Shares**”).

Unless otherwise defined herein, capitalised terms in the following table shall have the meanings ascribed to them in the Rules of the ESOS.

Date of Grant	6 April 2021
Acquisition Price of Options granted	S\$5.1135, being the Market Price. ¹
Total number of Options granted (including Options granted to Independent Directors)	1,020,000
Number of Options granted to each Director and Controlling Shareholder (and each of their Associates), if any	<u>Independent Directors</u> Mr James Rowan 150,000 Ms Ong Siew Koon @ Ong Siew Khoon 50,000 Mr Kristian John Robinson 50,000 Ms Lee Lee Khoon 50,000

Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited are the Joint Issue Managers for the Offering. Citigroup Global Markets Singapore Pte. Ltd., Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited are the Joint Global Coordinators for the Offering. Citigroup Global Markets Singapore Pte. Ltd., CLSA Singapore Pte Ltd, Credit Suisse (Singapore) Limited and Oversea-Chinese Banking Corporation Limited are the Joint Bookrunners and Underwriters for the Offering. The Joint Issue Managers, the Joint Global Coordinators and the Joint Bookrunners and Underwriters assume no responsibility for the contents of this announcement.

Market price of Shares on the Date of Grant (volume-weighted average)	S\$5.1701
Validity and Exercise Period of the Options granted to eligible employees	The Options are valid for a period of 10 years (including the respective vesting periods) from the Date of Grant and are exercisable as follows: <ul style="list-style-type: none"> - 6 April 2022 25% - 6 April 2023 25% - 6 April 2024 25% - 6 April 2025 25%
Validity and Exercise Period of the Options granted to Independent Directors	The Options are valid for a period of 5 years (including the respective vesting periods) from the Date of Grant and are exercisable as follows: <ul style="list-style-type: none"> - 6 April 2022 25% - 6 April 2023 25% - 6 April 2024 25% - 6 April 2025 25%

Note:

- (1) **“Market Price”** is defined in the Rules of the ESOS to mean a price determined by the Committee to be equal to the volume-weighted average price for the Shares on the Singapore Exchange over the three consecutive Trading Days immediately preceding the Date of Grant of that Option, as determined by the Committee by reference to the daily official list or any other publication published by the Singapore Exchange

**BY ORDER OF THE BOARD
NANOFILM TECHNOLOGIES INTERNATIONAL LIMITED**

Kay Lim Kian Onn
Chief Financial Officer
6 April 2021